Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | Radiotherapy before progression linked to lower TIL infiltration in patients with brain metastasis

Ariane Steindl • 26 Oct 2026
ESMO 2026
General

Ariane Steindl, PhD, Medical University of Vienna, Vienna, Austria, discusses a study investigating inflammatory and epigenetic signatures in progressive brain metastases, highlighting that patients who received radiotherapy before progression had lower infiltration of tumor-infiltrating lymphocytes (TILs) and higher infiltration of immunosuppressive markers. The analysis revealed an immune remodeling in progressive brain metastasis after radiotherapy, with an indication of increased immunosuppression in some patients, although no direct genetic or epigenetic drivers of progression were found. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Ariane Steindl

Highlights in brain metastasis research at ESMO 2026
1:31
Highlights in brain metastasis research at ESMO 2026
Ariane Steindl • 26 Oct 2026
Neurological symptoms independently associated with worse prognosis for melanoma brain metastasis
2:13
Neurological symptoms independently associated with worse prognosis for melanoma brain metastasis
Ariane Steindl • 26 Oct 2026
Key takeaways from ESMO 2022 in brain metastases
0:52
Key takeaways from ESMO 2022 in brain metastases
Ariane Steindl • 12 Sep 2022
Recent advances in the systemic treatment of brain metastases
1:07
Recent advances in the systemic treatment of brain metastases
Ariane Steindl • 12 Sep 2022

Related Videos

Evaluating SL-28 allogeneic leukocyte therapy in advanced solid tumors
1:49
Evaluating SL-28 allogeneic leukocyte therapy in advanced solid tumors
George Tetz • 25 Oct 2026
HS-20122, an EGFR/cMET bispecific antibody-drug conjugate, in solid tumors
1:40
HS-20122, an EGFR/cMET bispecific antibody-drug conjugate, in solid tumors
Hongyun Zhao • 24 Oct 2026
Comparing the toxicity of HS-20122, a bispecific ADC, to other ADCs
1:02
Comparing the toxicity of HS-20122, a bispecific ADC, to other ADCs
Hongyun Zhao • 24 Oct 2026
Patient-reported toxicity precedes dose-limiting toxicities in Phase I trials
0:46
Patient-reported toxicity precedes dose-limiting toxicities in Phase I trials
Kaissa Ouali • 24 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals